Biological Lattice Industries (BLI) Secures $1.8 Million Pre-Seed Funding Led by Uni.Fund to Democratize Biofabrication
18.10.2024 16:00:00 CEST | Business Wire | Press Release
Biological Lattice Industries Corp. (BLI), a leading innovator in biofabrication and life sciences R&D, today announced the successful closing of a $1.8 million pre-seed investment round led by Greek venture capital firm Uni.Fund. In conjunction with this funding announcement , BLI is introducing its first all-in-one solution for biofabrication: BioLoom™, BLI's advanced multi-tool 3D bioprinter and Loominus Studio™, its unified software platform designed to revolutionize biofabrication workflows.
BLI, a US startup with R&D operations in Greece, aims to radically simplify biofabrication for the global R&D community by providing intelligent, automated tools that streamline the design, fabrication, and testing of biomaterials. Biomaterials are critical for a wide array of biological applications. The applications range from advanced 3D cell culture systems for human biology emulation to the next-generation of resorbable medical devices and drug delivery systems for tissue trauma repair.
“We are thrilled to partner with Uni.Fund to bring our vision of democratizing biofabrication to life,” said Filippos Tourlomousis, Founder and CEO of BLI. “This funding will allow us to accelerate the development of our unified platform, enabling researchers to work with greater precision, reproducibility, and efficiency.”
Loominus Studio: A Unified Platform for Biofabrication
Current biofabrication workflows often require the coordination of multiple protocols, parameters and instruments, none of which are integrated. Loominus Studio™, BLI’s software offering, integrates every aspect of the biofabrication workflow, from design to fabrication. This all-in-one solution allows researchers to automate complex workflows, improving reproducibility and reducing the effort required to optimize biofabrication processes.
“Loominus Studio represents a new standard in biofabrication, allowing labs to focus on innovation rather than the technical challenges of integration,” said Filippos Tourlomousis. “Our goal is to make biofabrication as simple and intuitive as possible, empowering researchers to break through technical barriers.”
BioLoom™: Beyond Basic Bioprinting
At the core of BLI’s growing tool ecosystem is BioLoom™, a versatile multi-tool extrusion-based 3D bioprinter that can fabricate high-resolution multi-material architected scaffolds and devices. With its Active Environmental Control feature, BioLoom ensures reproducibility and supports Good Manufacturing Practice (GMP) compliance, making it ideal for labs focused on accelerating commercialization in life sciences.
“BioLoom provides an unparalleled level of versatility and precision,” added Tourlomousis. “It is designed to meet the needs of both academic and commercial labs, pushing the boundaries of biofabrication beyond traditional 3D bioprinting capabilities.”
The Role of Uni.Fund in Supporting Deep Tech Innovation
Uni.Fund, a venture capital firm committed to supporting world-class deep tech startups in Europe, sees BLI as a transformative force in biofabrication. “BLI is a game-changer in the biotech space, with a bold vision to disrupt how biofabrication is performed globally,” said Katerina Pramatari, Founding Partner at Uni.Fund. “Their integrated approach to life sciences R&D, combining sophisticated hardware and software powered by AI, is exactly the kind of innovation that Uni.Fund aims to support.”
Shaping the Future of Biofabrication Labs
With its ambitious vision, BLI aims to establish Loominus as the industry standard for biofabrication labs, offering a continuously growing array of tools and features that simplify complex workflows. The investment will accelerate the market availability of BioLoom and Loominus Studio that have already deployed to leading academic labs through the company’s early adopter’s customer program.
About Biological Lattice Industries (BLI)
Biological Lattice Industries Corp. (BLI) is a venture-backed startup founded in 2021 with the goal of democratizing biofabrication for life sciences R&D. BLI's platform, Loominus Studio, and its ecosystem of integrated hardware tools, including the BioLoom bioprinter, aim to revolutionize the way biomaterials are designed, fabricated, and tested.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241017262971/en/
Contacts
Media
info@biolattice.ai
Investor
Filippos Tourlomousis
filippos@biolattice.ai
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press Release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press Release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press Release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press Release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press Release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom